SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer

International Journal of Cancer

Volumn 121, Issue 3, 2007, Pages 615-620

  Skytt, Åsa ^a   Thysell, Elin ^a   Stattin, Pär ^a   Stenman, Ulf Håkan ^b   Antti, Henrik ^a   Wikström, Pernilla ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Plasma; Prospective; Prostate cancer; Proteomics; PSA

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PLASMA; PRIORITY JOURNAL; PROSTATE CANCER; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 34250869494     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22722     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellström M, Hugosson J, Lundgren R, Stattin P, Tomblom M, Johansson JE. The national prostate cancer register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 2005;39:117-23.
3. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walch PC, Scardino PT, Lange PH, Subong ENP, et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998;279:1542-47.
4. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urological Oncology: Seminars and Original Investigations 2006;24:46-50.
5. Omstein DK, Petricoin EF. Proteomics to diagnose human tumors and provide prognostic information. Oncology 2004;18:521-9.
6. Bons JAP, Wodzig WKWH, van Dieijen-Visser MP. Protein profiling as a diagnostic tool in clinical chemistry: a review. Clin Chem Lab Med 2005;43:1281-90.
7. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL, Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
8. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;148:1835-43.
9. Petricoin EF, III, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
10. Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15 ng/ml. J Urol 2004;172:1302-05.
11. Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman U-H, Egevad L, Riboli E, Hallmans G, Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000;92: 1910-7.
12. Weinehall L, Hallgren CG, Westman G, Janlert U, Wall S. Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care 1998;16:171-6.
13. International Union Against Cancer. TNM classification of malignant tumors, 4th edn. Berlin, Germany: Springer, 1992.
14. Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of tumours; in International histological classification of tumours No. 22. Geneva: World Health Organization, 1980.
15. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002;89:538-42.
16. Stocks T, Lukanova A, Rinaldi S, Biessy C, Dossus L, Lindahl B, Hallmans G, Kaaks R, Stattin S. Insulin resistance is inversely related to prostate cancer; a prospective study in Northern Sweden. Int J Cancer 2007 [Epub ahead of print].
17. Stattin P, Rinaldi S, Biessy C, Stenman U-H, Hallmans G, Kaaks R. High levels of insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 2004;22:3104-12.
18. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemometrics 2002;16:119-28.
19. Wibom C, Pettersson F, Sjöström M, Henriksson R, Johansson M, Bergenheim AT. Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment. Br J Cancer 2006;94:1853-63.
20. Coombes KR, Morris JS, Hu J, Edmonson SR, Beggerly KA. Serum proteomics profiling - a young technology begins to mature. Nat Biotechnolo 2005;23:291-2.
21. Diamandis E. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Nat Cancer Inst 2004;96:353-56.
22. Le L, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 2005;51:695-707.
23. Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam B-L, Diaz JI, Semmes OJ. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005;11:1073-85.
24. Zhang Z, Bast RC, Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64: 5882-90.
25. Moore LE, Fung ET, McGuire M, Rabkin CC, Molinaro A, Wang Z, Zhang F, Wang J, Yip C, Meng X-Y, Pfiffer R. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006;15:1641-6.
26. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006;116:26-30.
27. Villanueva J, Shaffer DR, Philips J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland E et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116: 271-84.
28. Tammen H, Schule I, Hess R, Menzel C, Kellmann M, Mohring T, Schulz-Knappe P. Pepdidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005;5:3414-22.